The team at Harmony Biosciences is excited to share that they have reached their enrollment goal for the Phase 3 RECONNECT trial and screening has officially closed.
A message to the Fragile X community from Dr. Kumar Budur, Chief Medical & Scientific Officer at Harmony Biosciences:
learn more
Visit the RECONNECT MyFXReserach post for more infromation:
Clinical Trial RECONNECT: ZYN002 Gel | MyFXResearch Portal (fragilex.org)
Project WellCAST: Caregivers of Children with Fragile X Needed for a Research Study
The Kelleher Lab at Purdue University is conducting a virtual, NIH-funded clinical trial called Project WellCAST. Project WellCAST aims to understand how to best support caregivers of children with rare neurogenetic conditions, including Fragile X syndrome.
Summary of the Fragile X Messenger Ribonucleoprotein (FMRP) Series at the 18th NFXF International Conference
Dr. Talia Thompson summarizes the Fragile X Messenger Ribonucleoprotein (FMRP) series from the 18th NFXF International Conference